Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.2K | $260K | $260K | $15.4K | $13.5K | — | $0.00 | $300K | $0.00 | $0.00 |
| Revenue growth | — | 1500.4% | 0.0% | -94.1% | -12.2% | — | — | — | -100.0% | — |
| Operating income | -$20.6M | -$13.3M | -$8.26M | -$8.63M | -$9.30M | -$41.9M | -$15.7M | -$13.1M | -$14.9M | -$18.1M |
| Operating margin | -127027.2% | -5118.1% | -3176.7% | -56071.8% | -68764.8% | — | — | -4356.7% | — | — |
| Net income | -$21.1M | -$15.7M | -$4.92M | -$8.35M | -$10.3M | -$26.6M | -$14.3M | -$12.3M | -$14.4M | -$16.8M |
| Net margin | -129721.8% | -6025.4% | -1894.1% | -54252.6% | -76346.2% | — | — | -4100.0% | — | — |
| EPS (diluted) | -$2.53 | -$1.20 | -$7.54 | -$3.80 | -$3.72 | -$169.74 | -$16.53 | -$27.01 | -$10.19 | -$0.30 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.6M | -$13.4M | -$7.69M | -$7.26M | -$4.77M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | -$10.8M |
| Capital expenditures | $98.1K | $11.4K | $1.71K | — | $6.00K | $0.00 | $10.0K | $4.00K | $0.00 | — |
| Free cash flow | -$15.7M | -$13.4M | -$7.69M | — | -$4.77M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15.2M | $6.67M | $5.79M | $5.11M | $713K | $10.5M | $12.4M | $12.4M | $9.82M | $133M |
| Total assets | $22.6M | $13.9M | $7.68M | $6.58M | $3.02M | $12.5M | $15.8M | $14.1M | $10.9M | $134M |
| Total liabilities | $11.3M | $5.37M | $1.63M | $1.46M | $10.1M | $5.15M | $3.28M | $2.74M | $3.39M | $4.96M |
| Long-term debt | — | — | — | — | $94.0K | $0.00 | — | — | — | — |
| Shareholders' equity | $11.3M | $8.52M | $6.05M | -$8.33M | -$16.6M | $7.37M | $12.5M | $11.3M | $7.49M | $129M |
| Retained earnings | -$193M | -$209M | -$214M | -$222M | -$238M | $94.6M | $109M | $122M | $136M | — |
| Shares (wtd avg diluted) | 11.0M | 15.2M | 910K | 3.87M | 2.77M | 187K | 880K | 456K | 1.42M | 55.7M |
Every figure is extracted from PALISADE BIO, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.